

Reference: FOI.ICB-2526/097

Subject: Tirzepatide (Mounjaro)

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
1. Was tirzepatide available through primary care services in the ICB area to patients with obesity as of 23 June 2025?	<p>We did not have the correct infrastructure safely in place on 23 June 2025 for primary care to deliver tirzepatide to patients as we were waiting on some national elements required for delivery to be shared.</p> <p>Tirzepatide could be offered to patients within a specialist weight management service as of 23 June 25.</p>
2. If not, when will the drug be available?	<p>We now have the correct infrastructure in place to support primary care to offer tirzepatide to patients. Primary care (General practice) have been sent a contract in the form of a LES and will be able to start the service once they have signed this. Therefore, anticipate this will start imminently.</p>
3. What criteria does/will the ICB set for determining eligibility for treatment? Please specify BMI level, any additional health criteria, and whether other factors are taken into account, eg weight loss required for surgery	<p>Specialist weight management services may prescribe tirzepatide within the NICE eligibility criteria for NICE TA1026</p> <p>Primary Care eligibility is in line with the NHSE NICE funding variation – cohort 1 as defined in the NHSE commissioning guidance.</p>

<p>4. How many people does the ICB calculate would be eligible for treatment in the first 12 months using the above criteria? If the calculation is based on financial year rather than the first 12 months from implementation date of the guidelines, please specify and use that figure.</p>	<p>Approximately 900. This data is taken from EMIS Web and based on current coding.</p>
<p>5. Is there a cap on how many eligible patients will be treated in the first 12 months/this financial year (please specify time period used)?</p>	<p>no</p>

The information provided in this response is accurate as of 11 July 2025 and has been approved for release by Debbie Campbell, Chief Pharmacist and Director of Medicines Optimisation for NHS Bristol, North Somerset and South Gloucestershire ICB.